Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) — Tangible Net Worth Ratio
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) has a Tangible Net Worth Ratio of 100.0% as of December 2024. This metric is calculated by deducting intangible assets ($0.00) from net assets ($409.61K) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See how liquid is Lakewood-Amedex Biotherapeutics Inc. Com's working capital to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Lakewood-Amedex Biotherapeutics Inc. Common Stock Tangible Net Worth Ratio (2023–2024)
This chart shows how Lakewood-Amedex Biotherapeutics Inc. Common Stock's Tangible Net Worth Ratio has changed across 2 annual periods from 2023 to 2024. As of December 2024, the ratio stands at 100.0%, reflecting net assets of $409.61K with intangible assets of $0.00 USD. Also explore net asset momentum of Lakewood-Amedex Biotherapeutics Inc. Com to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Lakewood-Amedex Biotherapeutics Inc. Common Stock (2023–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Lakewood-Amedex Biotherapeutics Inc. Common Stock from 2023 to 2024, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see LABT company net worth.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 100.0% | $409.61K | $0.00 | $1.07 Million | ▲ +0.0 pp |
| 2023 | 100.0% | $4.56 Million | $0.00 | $6.89 Million | — |